Skip to main content Accessibility help
×
Home
  • Print publication year: 2016
  • Online publication date: December 2016

Chapter 14 - The cognitive neurology of corticobasal degeneration and progressive supranuclear palsy

Related content

Powered by UNSILO
1.Rebeiz, JJ, Kolodny, EH, Richardson, EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Archives of Neurology. 1968;18(1):2033.
2.Gibb, WR, Luthert, PJ, Marsden, CD. Corticobasal degeneration. Brain: A Journal of Neurology. 1989;112(Pt 5):1171–92.
3.Riley, DE, Lang, AE, Lewis, A, Resch, L, Ashby, P, Hornykiewicz, O, et al. Cortical-basal ganglionic degeneration. Neurology. 1990;40(8):1203–12.
4.Constantinidis, J, Richard, J, Tissot, R. Pick’s disease. Histological and clinical correlations. European Neurology. 1974;11(4):208–17.
5.Lee, SE, Rabinovici, GD, Mayo, MC, Wilson, SM, Seeley, WW, DeArmond, SJ, et al. Clinicopathological correlations in corticobasal degeneration. Annals of Neurology. 2011;70(2):327–40.
6.Vanvoorst, WA, Greenaway, MC, Boeve, BF, Ivnik, RJ, Parisi, JE, Eric Ahlskog, J, et al. Neuropsychological findings in clinically atypical autopsy confirmed corticobasal degeneration and progressive supranuclear palsy. Parkinsonism & Related Disorders. 2008;14(4):376–8.
7.Grimes, DA, Lang, AE, Bergeron, CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology. 1999;53(9):1969–74.
8.Murray, R, Neumann, M, Forman, MS, Farmer, J, Massimo, L, Rice, A, et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology. 2007;68(16):1274–83.
9.Kertesz, A, McMonagle, P, Blair, M, Davidson, W, Munoz, DG. The evolution and pathology of frontotemporal dementia. Brain: A Journal of Neurology. 2005;128(Pt 9):19962005.
10.Geda, YE, Boeve, BF, Negash, S, Graff-Radford, NR, Knopman, DS, Parisi, JE, et al. Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. The Journal of Neuropsychiatry and Clinical Neurosciences. 2007;19(1):7780.
11.Wakabayashi, K, Oyanagi, K, Makifuchi, T, Ikuta, F, Homma, A, Homma, Y, et al. Corticobasal degeneration: etiopathological significance of the cytoskeletal alterations. Acta Neuropathologica. 1994;87(6):545–53.
12.Grundke-Iqbal, I, Iqbal, K, Quinlan, M, Tung, YC, Zaidi, MS, Wisniewski, HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. The Journal of Biological Chemistry. 1986;261(13):6084–9.
13.Witman, GB, Cleveland, DW, Weingarten, MD, Kirschner, MW. Tubulin requires tau for growth onto microtubule initiating sites. Proceedings of the National Academy of Sciences of the USA. 1976;73(11):4070–4.
14.Buee Scherrer, V, Hof, PR, Buee, L, Leveugle, B, Vermersch, P, Perl, DP, et al. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick’s disease. Acta Neuropathologica. 1996;91(4):351–9.
15.Cairns, NJ, Bigio, EH, Mackenzie, IR, Neumann, M, Lee, VM, Hatanpaa, KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathologica. 2007;114(1):522.
16.Dickson, DW, Bergeron, C, Chin, SS, Duyckaerts, C, Horoupian, D, Ikeda, K, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. Journal of Neuropathology and Experimental Neurology. 2002;61(11):935–46.
17.Komori, T, Arai, N, Oda, M, Nakayama, H, Mori, H, Yagishita, S, et al. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathologica. 1998;96(4):401–8.
18.Feany, MB, Dickson, DW. Widespread cytoskeletal pathology characterizes corticobasal degeneration. American Journal of Pathology. 1995;146(6):1388–96.
19.Togasaki, DM, Tanner, CM. Epidemiologic aspects. Advances in Neurology. 2000;82:53–9.
20.Nath, U, Burn, DJ. The epidemiology of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Parkinsonism & Related Disorders. 2000;6(3):145–53.
21.Morimatsu, M, Negoro, K. [Provisional diagnostic criteria of corticobasal degeneration (CBD) and the survey of patients with CBD in Japan]. Rinsho Shinkeigaku. 2002;42(11):1150–3.
22.Wenning, GK, Litvan, I, Jankovic, J, Granata, R, Mangone, CA, McKee, A, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. Journal of Neurology, Neurosurgery, and Psychiatry. 1998;64(2):184–9.
23.Mahapatra, RK, Edwards, MJ, Schott, JM, Bhatia, KP. Corticobasal degeneration. The Lancet Neurology. 2004;3(12):736–43.
24.Bugiani, O, Murrell, JR, Giaccone, G, Hasegawa, M, Ghigo, G, Tabaton, M, et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. Journal of Neuropathology and Experimental Neurology. 1999;58(6):667–77.
25.Spillantini, MG, Yoshida, H, Rizzini, C, Lantos, PL, Khan, N, Rossor, MN, et al. A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Annals of Neurology. 2000;48(6):939–43.
26.Rossi, G, Marelli, C, Farina, L, Laura, M, Maria Basile, A, Ciano, C, et al. The G389R mutation in the MAPT gene presenting as sporadic corticobasal syndrome. Movement Disorders: Official Journal of the Movement Disorder Society. 2008;23(6):892–5.
27.Yu, CE, Bird, TD, Bekris, LM, Montine, TJ, Leverenz, JB, Steinbart, E, et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Archives of Neurology. 2010;67(2):161–70.
28.Rohrer, JD, Beck, J, Warren, JD, King, A, Al Sarraj, S, Holton, J, et al. Corticobasal syndrome associated with a novel 1048_1049insG progranulin mutation. Journal of Neurology, Neurosurgery, and Psychiatry. 2009;80(11):1297–8.
29.Masellis, M, Momeni, P, Meschino, W, Heffner, R Jr., Elder, J, Sato, C, et al. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain: a Journal of Neurology. 2006;129(Pt 11):3115–23.
30.Conrad, C, Amano, N, Andreadis, A, Xia, Y, Namekataf, K, Oyama, F, et al. Differences in a dinucleotide repeat polymorphism in the tau gene between Caucasian and Japanese populations: implication for progressive supranuclear palsy. Neuroscience Letters. 1998;250(2):135–7.
31.Evans, W, Fung, HC, Steele, J, Eerola, J, Tienari, P, Pittman, A, et al. The tau H2 haplotype is almost exclusively Caucasian in origin. Neuroscience Letters. 2004;369(3):183–5.
32.Baker, M, Litvan, I, Houlden, H, Adamson, J, Dickson, D, Perez-Tur, J, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Human Molecular Genetics. 1999;8(4):711–15.
33.Houlden, H, Baker, M, Morris, HR, MacDonald, N, Pickering-Brown, S, Adamson, J, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56(12):1702–6.
34.Verpillat, P, Camuzat, A, Hannequin, D, Thomas-Anterion, C, Puel, M, Belliard, S, et al. Association between the extended tau haplotype and frontotemporal dementia. Archives of Neurology. 2002;59(6):935–9.
35.Hughes, A, Mann, D, Pickering-Brown, S. Tau haplotype frequency in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Experimental Neurology. 2003;181(1):1216.
36.Sobrido, MJ, Abu-Khalil, A, Weintraub, S, Johnson, N, Quinn, B, Cummings, JL, et al. Possible association of the tau H1/H1 genotype with primary progressive aphasia. Neurology. 2003;60(5):862–4.
37.Kertesz, A, Martinez-Lage, P, Davidson, W, Munoz, DG. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology. 2000;55(9):1368–75.
38.Graham, NL, Bak, TH, Hodges, JR. Corticobasal degeneration as a cognitive disorder. Movement Disorders: Official Journal of the Movement Disorder Society. 2003;18(11):1224–32.
39.Pillon, B, Blin, J, Vidailhet, M, Deweer, B, Sirigu, A, Dubois, B, et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology. 1995;45(8):1477–83.
40.Belfor, N, Amici, S, Boxer, AL, Kramer, JH, Gorno-Tempini, ML, Rosen, HJ, et al. Clinical and neuropsychological features of corticobasal degeneration. Mechanisms of Ageing and Development. 2006;127(2):203–7.
41.Gorno-Tempini, ML, Hillis, AE, Weintraub, S, Kertesz, A, Mendez, M, Cappa, SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–14.
42.Boeve, BF, Maraganore, DM, Parisi, JE, Ahlskog, JE, Graff-Radford, N, Caselli, RJ, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology. 1999;53(4):795800.
43.Josephs, KA, Dickson, DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Movement Disorders: Official Journal of the Movement Disorder Society. 2003;18(9):1018–26.
44.Josephs, KA, Petersen, RC, Knopman, DS, Boeve, BF, Whitwell, JL, Duffy, JR, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;66(1):41–8.
45.Rohrer, JD, Geser, F, Zhou, J, Gennatas, ED, Sidhu, M, Trojanowski, JQ, et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology. 2010;75(24):2204–11.
46.Rascovsky, K, Hodges, JR, Knopman, D, Mendez, MF, Kramer, JH, Neuhaus, J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain: A Journal of Neurology. 2011;134(Pt 9):2456–77.
47.Litvan, I, Agid, Y, Goetz, C, Jankovic, J, Wenning, GK, Brandel, JP, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology. 1997;48(1):119–25.
48.Mackenzie, IR, Neumann, M, Bigio, EH, Cairns, NJ, Alafuzoff, I, Kril, J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica. 2010;119(1):14.
49.Josephs, KA, Duffy, JR, Strand, EA, Whitwell, JL, Layton, KF, Parisi, JE, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain: A Journal of Neurology. 2006;129(Pt 6):1385–98.
50.Armstrong, MJ, Litvan, I, Lang, AE, Bak, TH, Bhatia, KP, Borroni, B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496503.
51.Ling, H, O’Sullivan, SS, Holton, JL, Revesz, T, Massey, LA, Williams, DR, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain: A Journal of Neurology. 2010;133(Pt 7):2045–57.
52.Hu, WT, Rippon, GW, Boeve, BF, Knopman, DS, Petersen, RC, Parisi, JE, et al. Alzheimer’s disease and corticobasal degeneration presenting as corticobasal syndrome. Movement Disorders: Official Journal of the Movement Disorder Society. 2009;24(9):1375–9.
53.Shelley, BP, Hodges, JR, Kipps, CM, Xuereb, JH, Bak, TH. Is the pathology of corticobasal syndrome predictable in life? Movement Disorders: Official Journal of the Movement Disorder Society. 2009;24(11):1593–9.
54.Rivaud-Pechoux, S, Vidailhet, M, Gallouedec, G, Litvan, I, Gaymard, B, Pierrot-Deseilligny, C. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology. 2000;54(5):1029–32.
55.Garbutt, S, Matlin, A, Hellmuth, J, Schenk, AK, Johnson, JK, Rosen, H, et al. Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer’s disease. Brain: A Journal of Neurology. 2008;131(Pt 5):1268–81.
56.Vidailhet, M, Rivaud, S, Gouider-Khouja, N, Pillon, B, Bonnet, AM, Gaymard, B, et al. Eye movements in parkinsonian syndromes. Annals of Neurology. 1994;35(4):420–6.
57.Rottach, KG, Riley, DE, DiScenna, AO, Zivotofsky, AZ, Leigh, RJ. Dynamic properties of horizontal and vertical eye movements in Parkinsonian syndromes. Annals of Neurology. 1996;39(3):368–77.
58.Rivaud-Pechoux, S, Vidailhet, M, Brandel, JP, Gaymard, B. Mixing pro- and antisaccades in patients with Parkinsonian syndromes. Brain: A Journal of Neurology. 2007;130(Pt 1):256–64.
59.Boxer, AL, Garbutt, S, Seeley, WW, Jafari, A, Heuer, HW, Mirsky, J, et al. Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease. Archives of Neurology. 2012;69(4):509–17.
60.Groschel, K, Hauser, TK, Luft, A, Patronas, N, Dichgans, J, Litvan, I, et al. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. NeuroImage. 2004;21(2):714–24.
61.Hassan, A, Whitwell, JL, Boeve, BF, Jack, CR Jr., Parisi, JE, Dickson, DW, et al. Symmetric corticobasal degeneration (S-CBD). Parkinsonism & Related Disorders. 2010;16(3):208–14.
62.Josephs, KA, Whitwell, JL, Dickson, DW, Boeve, BF, Knopman, DS, Petersen, RC, et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiology of Aging. 2008;29(2):280–9.
63.Steele, JC, Richardson, JC, Olszewski, J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Archives of Neurology. 1964;10:333–59.
64.Chambers, CB, Lee, JM, Troncoso, JC, Reich, S, Muma, NA. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer’s disease. Annals of Neurology. 1999;46(3):325–32.
65.Steele, JC. Progressive supranuclear palsy. Brain: A Journal of Neurology. 1972;95(4):693704.
66.David, NJ, Mackey, EA, Smith, JL. Further observations in progressive supranuclear palsy. Neurology. 1968;18(4):349–56.
67.Litvan, I, Agid, Y, Calne, D, Campbell, G, Dubois, B, Duvoisin, RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):19.
68.Osaki, Y, Ben-Shlomo, Y, Lees, AJ, Daniel, SE, Colosimo, C, Wenning, G, et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Movement Disorders: Official Journal of the Movement Disorder Society. 2004;19(2):181–9.
69.Litvan, I, Agid, Y, Jankovic, J, Goetz, C, Brandel, JP, Lai, EC, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996;46(4):922–30.
70.Hughes, AJ, Daniel, SE, Ben-Shlomo, Y, Lees, AJ. The accuracy of diagnosis of Parkinsonian syndromes in a specialist movement disorder service. Brain: A Journal of Neurology. 2002;125(Pt 4):861–70.
71.Daniel, SE, de Bruin, VM, Lees, AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain: a Journal of Neurology. 1995;118 ( Pt 3):759–70.
72.Litvan, I, Grimes, DA, Lang, AE, Jankovic, J, McKee, A, Verny, M, et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. Journal of Neurology. 1999;246 (Suppl 2):II1–15.
73.Morris, HR, Gibb, G, Katzenschlager, R, Wood, NW, Hanger, DP, Strand, C, et al. Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain: A Journal of Neurology. 2002;125(Pt 5):969–75.
74.Wadia, PM, Lang, AE. The many faces of corticobasal degeneration. Parkinsonism & Related Disorders. 2007;13(Suppl 3):S336–40.
75.Lantos, PL. The neuropathology of progressive supranuclear palsy. Journal of Neural Transmission Supplementum. 1994;42:137–52.
76.Williams, DR, de Silva, R, Paviour, DC, Pittman, A, Watt, HC, Kilford, L, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-Parkinsonism. Brain : A Journal of Neurology. 2005;128(Pt 6):1247–58.
77.Williams, DR, Holton, JL, Strand, C, Pittman, A, de Silva, R, Lees, AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-Parkinsonism from Richardson’s syndrome. Brain: A Journal of Neurology. 2007;130(Pt 6):1566–76.
78.Williams, DR, Holton, JL, Strand, K, Revesz, T, Lees, AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Movement Disorders: Official Journal of the Movement Disorder Society. 2007;22(15):2235–41.
79.Dickson, DW, Ahmed, Z, Algom, AA, Tsuboi, Y, Josephs, KA. Neuropathology of variants of progressive supranuclear palsy. Current Opinion in Neurology. 2010;23(4):394400.
80.Tagliavini, F, Pilleri, G, Bouras, C, Constantinidis, J. The basal nucleus of Meynert in patients with progressive supranuclear palsy. Neuroscience Letters. 1984;44(1):3742.
81.Nishimura, M, Namba, Y, Ikeda, K, Oda, M. Glial fibrillary tangles with straight tubules in the brains of patients with progressive supranuclear palsy. Neuroscience Letters. 1992;143(1–2):35–8.
82.Matsusaka, H, Ikeda, K, Akiyama, H, Arai, T, Inoue, M, Yagishita, S. Astrocytic pathology in progressive supranuclear palsy: significance for neuropathological diagnosis. Acta Neuropathologica. 1998;96(3):248–52.
83.Arima, K, Nakamura, M, Sunohara, N, Ogawa, M, Anno, M, Izumiyama, Y, et al. Ultrastructural characterization of the tau-immunoreactive tubules in the oligodendroglial perikarya and their inner loop processes in progressive supranuclear palsy. Acta Neuropathologica. 1997;93(6):558–66.
84.Nath, U, Ben-Shlomo, Y, Thomson, RG, Morris, HR, Wood, NW, Lees, AJ, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain: A Journal of Neurology. 2001;124(Pt 7):1438–49.
85.Schrag, A, Ben-Shlomo, Y, Quinn, NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354(9192):1771–5.
86.Bower, JH, Maraganore, DM, McDonnell, SK, Rocca, WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology. 1997;49(5):1284–8.
87.Maher, ER, Lees, AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1986;36(7):1005–8.
88.Golbe, LI, Davis, PH, Schoenberg, BS, Duvoisin, RC. Prevalence and natural history of progressive supranuclear palsy. Neurology. 1988;38(7):1031–4.
89.Donker Kaat, L, Boon, AJ, Azmani, A, Kamphorst, W, Breteler, MM, Anar, B, et al. Familial aggregation of parkinsonism in progressive supranuclear palsy. Neurology. 2009;73(2):98105.
90.Dickson, DW, Rademakers, R, Hutton, ML. Progressive supranuclear palsy: pathology and genetics. Brain Pathology. 2007;17(1):7482.
91.Hoglinger, GU, Melhem, NM, Dickson, DW, Sleiman, PM, Wang, LS, Klei, L, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics. 2011;43(7):699705.
92.Golbe, LI, Davis, PH, Lepore, FE. Eyelid movement abnormalities in progressive supranuclear palsy. Movement Disorders: Official Journal of the Movement Disorder Society. 1989;4(4):297302.
93.Nath, U, Ben-Shlomo, Y, Thomson, RG, Lees, AJ, Burn, DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology. 2003;60(6):910–16.
94.Donker Kaat, L, Boon, AJ, Kamphorst, W, Ravid, R, Duivenvoorden, HJ, van Swieten, JC. Frontal presentation in progressive supranuclear palsy. Neurology. 2007;69(8):723–9.
95.Kertesz, A, McMonagle, P. Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy. Journal of the Neurological Sciences. 2010;289(1–2):138–43.
96.Litvan, I, Mega, MS, Cummings, JL, Fairbanks, L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology. 1996;47(5):1184–9.
97.Pillon, B, Gouider-Khouja, N, Deweer, B, Vidailhet, M, Malapani, C, Dubois, B, et al. Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson’s disease and progressive supranuclear palsy. Journal of Neurology, Neurosurgery, and Psychiatry. 1995;58(2):174–9.
98.Arai, H, Morikawa, Y, Higuchi, M, Matsui, T, Clark, CM, Miura, M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochemical and Biophysical Research Communications. 1997;236(2):262–4.
99.Noguchi, M, Yoshita, M, Matsumoto, Y, Ono, K, Iwasa, K, Yamada, M. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. Journal of the Neurological Sciences. 2005;237(1–2):61–5.
100.Urakami, K, Wada, K, Arai, H, Sasaki, H, Kanai, M, Shoji, M, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. Journal of the Neurological Sciences. 2001;183(1):95–8.
101.Mitani, K, Furiya, Y, Uchihara, T, Ishii, K, Yamanouchi, H, Mizusawa, H, et al. Increased CSF tau protein in corticobasal degeneration. Journal of Neurology. 1998;245(1):44–6.
102.Verbeek, MM, Abdo, WF, De Jong, D, Horstink, MW, Kremer, BP, Bloem, BR. Cerebrospinal fluid Abeta42 levels in multiple system atrophy. Movement Disorders: Official Journal of the Movement Disorder Society. 2004;19(2):238–40; author reply 40–1.
103.Holmberg, B, Johnels, B, Blennow, K, Rosengren, L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson’s disease and progressive supranuclear palsy. Movement Disorders: Official Journal of the Movement Disorder Society. 2003;18(2):186–90.
104.Brettschneider, J, Petzold, A, Sussmuth, SD, Landwehrmeyer, GB, Ludolph, AC, Kassubek, J, et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Movement Disorders: Official Journal of the Movement Disorder Society. 2006;21(12):2224–7.
105.Whitwell, JL, Jack, CR Jr., Boeve, BF, Parisi, JE, Ahlskog, JE, Drubach, DA, et al. Imaging correlates of pathology in corticobasal syndrome. Neurology. 2010;75(21):1879–87.
106.Oba, H, Yagishita, A, Terada, H, Barkovich, AJ, Kutomi, K, Yamauchi, T, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology. 2005;64(12):2050–5.
107.Quattrone, A, Nicoletti, G, Messina, D, Fera, F, Condino, F, Pugliese, P, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology. 2008;246(1):214–21.
108.Brenneis, C, Seppi, K, Schocke, M, Benke, T, Wenning, GK, Poewe, W. Voxel-based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. Journal of Neurology, Neurosurgery, and Psychiatry. 2004;75(2):246–9.
109.Boxer, AL, Geschwind, MD, Belfor, N, Gorno-Tempini, ML, Schauer, GF, Miller, BL, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Archives of Neurology. 2006;63(1):81–6.
110.Price, S, Paviour, D, Scahill, R, Stevens, J, Rossor, M, Lees, A, et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson’s disease. NeuroImage. 2004;23(2):663–9.
111.Okamura, N, Furumoto, S, Fodero-Tavoletti, MT, Mulligan, RS, Harada, R, Yates, P, et al. Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain: A Journal of Neurology. 2014;137(Pt 6): 1762–71.
112.Kompoliti, K, Goetz, CG, Litvan, I, Jellinger, K, Verny, M. Pharmacological therapy in progressive supranuclear palsy. Archives of Neurology. 1998;55(8):1099–102.
113.Stamelou, M, de Silva, R, Arias-Carrion, O, Boura, E, Hollerhage, M, Oertel, WH, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain: A Journal of Neurology. 133(Pt 6):1578–90.